Antidepressants are among the most prescribed medications in the United States, and patients on them sometimes notice increased shedding within the first few months of starting therapy. The question of whether the medication is the cause is common, and the evidence-based answer is more nuanced than a yes or no. Hair shedding has been reported with most antidepressant classes, but it appears to be uncommon, almost always reversible, and tied to a temporary shift in the hair growth cycle rather than direct toxicity to the follicle. The risk also varies meaningfully by drug class. This guide walks through what the comparative data actually shows, the mechanism most likely involved, and how to think about shedding that develops after starting an antidepressant.
What the comparative data shows
The most useful study on this question is a retrospective cohort analysis that compared hair loss reports across antidepressant classes in a population of over a million patients. Across the medications studied, bupropion was associated with the highest relative risk of reported hair loss, while fluoxetine, paroxetine, sertraline, and other SSRIs showed lower but still measurable rates. Mirtazapine had the lowest risk in the comparison (Etminan et al., Int Clin Psychopharmacol, 2018).
The absolute numbers are still small. The risk of a hair loss event being recorded in the first year of antidepressant use was on the order of 1 to 2 cases per thousand patients across the cohort, with bupropion at the higher end and the SSRIs lower. That is not nothing, but it is far from the rate of common side effects like nausea or sexual dysfunction. Most people who start an antidepressant will not experience clinically meaningful shedding.
Case reports and pharmacovigilance databases add some texture. Hair shedding has been described with essentially every SSRI (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), the SNRIs venlafaxine and duloxetine, bupropion, the tricyclics (amitriptyline, nortriptyline, imipramine), and less frequently with mirtazapine and trazodone (Mercke et al., Ann Clin Psychiatry, 2000). The pattern across these reports is consistent: diffuse shedding starting 2 to 4 months after initiation, gradual recovery after the drug is stopped or sometimes while it is continued.
The mechanism is almost always telogen effluvium
The clinical picture in essentially every documented case is the same diffuse, non-patterned shed seen after other physiologic stressors. This is telogen effluvium: a synchronized shift of follicles from the active growth phase (anagen) into the resting phase (telogen), followed several months later by a noticeable shed when those resting hairs are released.
Why an antidepressant would trigger this shift is not fully worked out. The leading hypotheses are that changes in serotonergic, noradrenergic, or dopaminergic signaling influence the neuroendocrine inputs to the follicle, and that the underlying depression itself (which often features sleep disruption, appetite changes, weight loss, and chronic stress) contributes to the same end pathway. In other words, it can be difficult in any individual case to separate the medication's effect from the effect of the condition being treated. Depression is itself a recognized cause of telogen effluvium.
The important clinical point is what telogen effluvium is not. It is not follicle death. It is not androgenetic alopecia. Follicles released into telogen by a transient stressor reenter anagen on the next cycle, and the hair regrows. The visible thinning during the shedding window can be alarming, but it is rarely permanent.
Class-by-class summary of what is known
The evidence is uneven across classes, and the differences in reported risk should be read as relative rather than absolute.
SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram). Hair shedding has been reported with all of them. The Etminan cohort found small but measurable risks across the class, with no clear standout within the group. Fluoxetine and paroxetine have the longest case-report literature simply because they have been available the longest.
SNRIs (venlafaxine, duloxetine). Similar profile to SSRIs in the comparative data. Both have case reports of diffuse shedding within the first few months of therapy, generally resolving on discontinuation.
Bupropion. The highest reported risk in the comparative cohort. The mechanism is unclear; bupropion's pharmacology (norepinephrine and dopamine reuptake inhibition) differs from the SSRIs and SNRIs, and it is also more commonly associated with weight loss, which can be a separate contributor to shedding.
Tricyclics (amitriptyline, nortriptyline, imipramine). A smaller and older case-report literature. Modern use is mostly for chronic pain and sleep at lower doses than the original antidepressant indications, which may obscure the risk profile.
Mirtazapine. The lowest reported risk in the Etminan comparison. Of note, mirtazapine is often associated with weight gain and improved sleep, which may run in the opposite direction of the stress and weight-loss pathway that contributes to other antidepressant-related shedding.
Trazodone. Rare case reports. Most clinical use is at low doses for sleep, and the literature does not support a substantial risk at those doses.
Timing and pattern
If antidepressant-related shedding develops, it usually follows a recognizable timeline:
- Onset 2 to 4 months after starting. This lag is characteristic of telogen effluvium. The follicles shift into the resting phase shortly after the trigger, but the visible shed comes when those resting hairs are released about 3 months later.
- Diffuse pattern. Shedding is spread across the whole scalp rather than concentrated at the temples, the crown, or the part line. Patients often describe seeing more hair in the shower, on the pillow, and in the brush rather than visible patches of thinning.
- Gradual recovery. Most cases resolve within 6 to 9 months of removing or stabilizing the trigger. Regrowth begins before the shedding fully stops, so density continues to look thin during the transition even when recovery is well underway.
A pattern that does not fit this timeline (loss concentrated at the hairline or crown, gradual rather than abrupt onset, no clear trigger 2 to 4 months earlier) is more consistent with pattern hair loss than with a drug-induced shed. The two can also coexist: an episode of telogen effluvium can unmask underlying androgenetic alopecia that was previously subclinical.
How to think about it if it happens to you
Stopping an antidepressant because of hair shedding is almost never the right first move. The trade-off is unfavorable: the medication is treating a condition with substantial morbidity, and the shedding is usually self-limited. A reasonable framework instead is:
- Wait for the timing to clarify. If shedding starts within 1 month of beginning an antidepressant, the timing is too early for telogen effluvium from that drug. Look for other triggers in the 2 to 4 months before the shed (illness, surgery, weight loss, an iron-deficient diet, postpartum, thyroid changes).
- Rule out the correctable causes. A focused workup of ferritin, TSH, vitamin D, and B12 will identify the contributors that are worth fixing regardless of the antidepressant question. Iron deficiency in particular is associated with worse hair loss outcomes in observational data (Trost et al., J Am Acad Dermatol, 2006).
- Discuss with the prescriber before switching. If the medication is genuinely the most likely contributor and shedding has not resolved after several months, the conversation with the prescriber is about whether a within-class switch (for example, to mirtazapine, which has the lowest reported risk) or a different class is reasonable given the underlying diagnosis. This is a decision that weighs psychiatric stability against cosmetic concern, and it is not a decision to make unilaterally.
- Give recovery time. Most patients who continue the medication and address other contributors see their shed resolve within 6 to 9 months. The thin appearance during recovery often looks worse than the underlying biology suggests.
When pattern hair loss is also part of the picture
A subset of patients on antidepressants are also in the demographic for pattern hair loss: men in their 20s, 30s, or 40s with a family history, or women approaching or past menopause. The shedding episode may be what brings them to a clinic, but the underlying condition is genetic miniaturization of the follicle, not the medication.
The two situations are managed differently. Drug-induced telogen effluvium resolves on its own when the trigger is corrected. Pattern hair loss does not resolve and requires treatment with minoxidil, finasteride, or both, when medically appropriate. A scalp exam by a physician or dermatologist is the most reliable way to tell which of the two situations is contributing, and many patients have both.
What this means in practice
If you have started an antidepressant in the last several months and are noticing more shedding than usual, the most likely explanation is a self-limited telogen effluvium that will resolve as the underlying biology stabilizes. The pattern, the timing, and the absence of patchy loss are the things to look at. Identifying and correcting any concurrent iron, B12, or thyroid issues is generally a higher-yield first step than stopping the medication.
If the loss is concentrated at the temples, the crown, or the part line rather than diffuse, or if it does not resolve within 6 to 9 months despite addressing other contributors, that is worth a separate conversation about whether pattern hair loss is part of the picture. Curekey's hair assessment is one way to start that conversation with a U.S.-licensed physician.
Related reading
- Does metformin cause hair loss?: the sibling article in the medication-side-effects cluster, with the B12 mechanism as a contrast.
- Does Ozempic, Wegovy, or Mounjaro cause hair loss?: another medication-linked telogen effluvium, this time tied to rapid weight loss.
- Stress and hair loss: telogen effluvium: the cycle-based explanation for the most common acute shedding pattern.
- Nutritional deficiencies that cause hair loss: which deficiencies are actually linked to shedding and what testing is useful.
- How it works: what a Curekey assessment and physician review look like.
